GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioArctic AB (OSTO:BIOA B) » Definitions » EV-to-FCF

BioArctic AB (OSTO:BIOA B) EV-to-FCF : 54.32 (As of May. 11, 2024)


View and export this data going back to 2017. Start your Free Trial

What is BioArctic AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BioArctic AB's Enterprise Value is kr16,822.9 Mil. BioArctic AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was kr309.7 Mil. Therefore, BioArctic AB's EV-to-FCF for today is 54.32.

The historical rank and industry rank for BioArctic AB's EV-to-FCF or its related term are showing as below:

OSTO:BIOA B' s EV-to-FCF Range Over the Past 10 Years
Min: -2232.15   Med: -39.7   Max: 194.4
Current: 51.64

During the past 9 years, the highest EV-to-FCF of BioArctic AB was 194.40. The lowest was -2232.15. And the median was -39.70.

OSTO:BIOA B's EV-to-FCF is ranked worse than
81.28% of 390 companies
in the Biotechnology industry
Industry Median: 6.365 vs OSTO:BIOA B: 51.64

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), BioArctic AB's stock price is kr203.00. BioArctic AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr2.590. Therefore, BioArctic AB's PE Ratio for today is 78.38.


BioArctic AB EV-to-FCF Historical Data

The historical data trend for BioArctic AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioArctic AB EV-to-FCF Chart

BioArctic AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only 22.45 -70.81 -66.72 -522.19 74.59

BioArctic AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -522.19 68.63 82.55 195.82 74.59

Competitive Comparison of BioArctic AB's EV-to-FCF

For the Biotechnology subindustry, BioArctic AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioArctic AB's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioArctic AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where BioArctic AB's EV-to-FCF falls into.



BioArctic AB EV-to-FCF Calculation

BioArctic AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=16822.917/309.694
=54.32

BioArctic AB's current Enterprise Value is kr16,822.9 Mil.
BioArctic AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr309.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioArctic AB  (OSTO:BIOA B) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

BioArctic AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=203.00/2.590
=78.38

BioArctic AB's share price for today is kr203.00.
BioArctic AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2.590.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


BioArctic AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of BioArctic AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BioArctic AB (OSTO:BIOA B) Business Description

Traded in Other Exchanges
Address
Warfvinges vag 35, Stockholm, SWE, SE-112 51
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. In addition, the group is also focused on the development of a treatment with a combination of a biodegradable medical device and a drug substance for complete spinal cord injury. Geographically, it derives a majority of its revenue from Asia.

BioArctic AB (OSTO:BIOA B) Headlines

No Headlines